Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 07, 2026 09:30 ET | Source: Merakris Therapeutics

Merakris Therapeutics Provides FDA Update and Reports Interim Findings for MTX-001 in Venous Leg Ulcers

RESEARCH TRIANGLE PARK, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Merakris Therapeutics today provided an update on recent communications with the U.S. Food and Drug Administration (FDA) related to its...
April 07, 2026 08:15 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform

Partnership to drive brand architecture, go-to-market execution, and global launch of the Company’s product portfolio bridging biotechnology and premium skincare MELVILLE, N.Y., April 07, 2026 ...
April 07, 2026 08:00 ET | Source: Evaxion

Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01

Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026The trial has already yielded encouraging one- and two-year data...
April 07, 2026 07:50 ET | Source: Artelo Biosciences

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop...
April 07, 2026 07:30 ET | Source: NervGen Pharma Corp.

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

Alignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic tetraplegia.Primary endpoint will be the change from baseline in GRASSP...
April 07, 2026 07:30 ET | Source: CervoMed Inc.

CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting

Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design Additional data from MRI analyses will...
April 07, 2026 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference

PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the...
April 07, 2026 07:30 ET | Source: Anavex Life Sciences Corp.

Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...
April 07, 2026 07:00 ET | Source: Climb Bio, Inc.

Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy

WELLESLEY HILLS, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,...
April 07, 2026 07:00 ET | Source: AC Immune SA

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and...